The company was established in North America in United States. The leading representative office of defined VC is situated in the Aliso Viejo.
The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 25 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. The fund is constantly included in 2-6 deals per year. The top amount of exits for fund were in 2018. This Visionary Venture Fund works on 11 percentage points less the average amount of lead investments comparing to the other organizations.
The usual cause for the fund is to invest in rounds with 2 partakers. Despite the Visionary Venture Fund, startups are often financed by Tigris Ventures, Sequoia Capital Israel, Flying L Partners. The meaningful sponsors for the fund in investment in the same round are Flying L Partners, Bluestem Capital, Vivo Capital. In the next rounds fund is usually obtained by Petrichor Healthcare Capital Management, Global Health Investment Fund (GHIF), Flying L Partners.
Among the most popular portfolio startups of the fund, we may highlight CorneaGen, Mynosys, Iantech. The fund has exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Chemical Engineering, Pharmaceutical.
The current fund was established by Ehsan Sadri.
Funds with similar focus
|Bayerische Motoren Werke||Bayern, Germany, Munich|
|Bitfury Group||Amsterdam, Noord-Holland, The Netherlands|
|Burch Investment Group||Nashville, Tennessee, United States|
|Digital Ventures||Australia, Perth, Western Australia|
|F&G Venture||China, Shanghai, Shanghai|
|Gibraltar Business Capital||Illinois, Northbrook, United States|
|Holdinvest||Argentina, Buenos Aires, Distrito Federal|
|Jianyin International Capital Management||-|
|Jiasufei Keji||Beijing, China, Haidian|
|New Harbor Capital||Chicago, Illinois, United States|
|NextWaveBio||Connecticut, East Hartford, United States|
|Qingdao Citymedia Co.||China, Qingdao Shi, Shandong|
|RITEK Corporation||China, Jiangsu, Taiwan|
|Saichen Jisheng||China, Hangzhou, Zhejiang|
|SANAD Fund||Frankfurt, Germany, Hessen|
|Sukna Ventures||Ar Riyad, Riyadh, Saudi Arabia|
|Thinktiv||Austin, Texas, United States|
|$120M||12 Apr 2022||Seattle, Washington, United States|
|$45M||10 Aug 2021||California, United States|
|$30M||10 Sep 2020||Israel, Tel Aviv District, Israel|
|$22M||11 Aug 2020||Boston, Massachusetts, United States|
|$3M||02 Jun 2020||Northern Ireland|
|$60M||08 Jan 2020||Irvine, California, United States|
|$21M||11 Jul 2018||California, United States|
|$13M||05 Jun 2018||Israel, Tel Aviv District, Israel|
Tear Film Innovations
|$8M||23 May 2018||Carlsbad, California, United States|
– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.